Fulcrum Therapeutics, Inc. (FULC)

7.14 +0.01 (+0.14%) At close: 04:00PM EDT

Fulcrum Therapeutics, Inc.

26 Landsdowne Street
Cambridge, MA 02139
United States
617 651 8851
https://www.fulcrumtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 76

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Iain Fraser DPHIL	Senior Vice President of Early Development	N/A	N/A	N/A
Ms. Kristina Storey	Senior Vice President of Regulatory Affairs & Quality Assurance	N/A	N/A	N/A
Dr. Patrick T. Horn M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1955

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Fulcrum Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 4; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.